276 related articles for article (PubMed ID: 19892863)
1. Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.
Dastjerdi MH; Saban DR; Okanobo A; Nallasamy N; Sadrai Z; Chauhan SK; Hajrasouliha AR; Dana R
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2411-7. PubMed ID: 19892863
[TBL] [Abstract][Full Text] [Related]
2. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
3. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
4. Avastin use in high risk corneal transplantation.
Vassileva PI; Hergeldzhieva TG
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1701-6. PubMed ID: 19680676
[TBL] [Abstract][Full Text] [Related]
5. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
7. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.
Dekaris I; Gabrić N; Drača N; Pauk-Gulić M; Miličić N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):287-94. PubMed ID: 25398659
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
9. Corneal graft surgery combined with subconjunctival bevacizumab (avastin).
Symes RJ; Poole TR
Cornea; 2010 Jun; 29(6):691-3. PubMed ID: 20458243
[TBL] [Abstract][Full Text] [Related]
10. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
12. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
Qian CX; Bahar I; Levinger E; Rootman D
Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
14. The effect of bevacizumab on corneal neovascularization in rabbits.
Kim WJ; Jeong HO; Chung SK
Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
16. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
17. Subconjunctival bevacizumab for corneal neovascularization.
Erdurmus M; Totan Y
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
[TBL] [Abstract][Full Text] [Related]
18. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.
Dastjerdi MH; Al-Arfaj KM; Nallasamy N; Hamrah P; Jurkunas UV; Pineda R; Pavan-Langston D; Dana R
Arch Ophthalmol; 2009 Apr; 127(4):381-9. PubMed ID: 19365012
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in High-Risk Corneal Transplantation: A Pilot Multicenter Prospective Randomized Control Trial.
Dohlman TH; McSoley M; Amparo F; Carreno-Galeano T; Wang M; Dastjerdi M; Singh RB; Coco G; Di Zazzo A; Shikari H; Saboo U; Sippel K; Ciralsky J; Yoo SH; Sticca M; Wakamatsu TH; Murthy S; Hamrah P; Jurkunas U; Ciolino JB; Gomes JAP; Perez VL; Yin J; Dana R
Ophthalmology; 2022 Aug; 129(8):865-879. PubMed ID: 35358592
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Pathologic Corneal Neovascularization by Topical Application of a Novel Peptide In Vivo.
Lu Y; Xu Y; Gu Q; Xu X
Cornea; 2015 Oct; 34(10):1295-302. PubMed ID: 26266428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
